Every Form 4 that Roivant Sciences Ltd. (ROIV) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow ROIV and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ROIV filings page.
Roivant Sciences Ltd. director Oren Ilan received an award of 810 Common Shares on October 23, 2026, under the issuer’s Non-Employee Director Compensation Plan. The award was fully vested as of the grant date. Oren Ilan directly held 124,490 Common Shares following the transaction.
Roivant Sciences Ltd. director Melissa B. Epperly received a fully vested award of 513 Common Shares on October 23, 2026, under the company’s Non-Employee Director Compensation Plan. On the same date, the issuer net settled 116 shares to satisfy tax-withholding obligations connected with vesting and settlement; the reported transaction price was $36.49 per share. No Rule 10b5-1 plan is reported.
Roivant Sciences Ltd. (ROIV) director James C. Momtazee received an award of 383 Common Shares under the Non-Employee Director Compensation Plan on October 23, 2026; the award was fully vested as of the grant date. On that date, the issuer net-settled 77 Common Shares to satisfy applicable tax withholding obligations, with a reported price of $36.49 per share.
Roivant Sciences Ltd. President and Immunovant CEO Eric Venker reported sales of 185,856 Common Shares at a weighted average price of $35.09 and 14,144 Common Shares at a weighted average price of $35.42 on October 20, 2026. Both sales were made under a Rule 10b5-1 trading plan adopted June 30, 2026. The first group sold at prices ranging from $34.38 to $35.38, inclusive; the second ranged from $35.39 to $35.51, inclusive.
Roivant Sciences Ltd. President & CIO and director Mayukh Sukhatme had 19,976 common shares withheld on October 16, 2026, through the issuer’s net settlement of performance restricted stock units to satisfy tax-withholding obligations after performance and service conditions were met. The reported price was $33.53 per share, and his reported direct holdings following the transaction were 18,563,884 common shares.
Additional PSUs that have satisfied both conditions will be settled in future installments. Shares issued on settlement, excluding those withheld for taxes, remain subject to a two-year holding period measured from satisfaction of the service condition.
Roivant Sciences Ltd. CEO and director Matthew Gline had 34,638 common shares withheld on October 16, 2026, at $33.53 per share to satisfy tax withholding obligations in the issuer’s net settlement of performance restricted stock units (PSUs). The settlement followed achievement of both performance- and service-based vesting conditions; Gline directly held 16,549,136 common shares afterward. Common shares issued from the PSU settlement, excluding shares withheld for taxes, are subject to a two-year holding period measured from satisfaction of the service condition. Additional PSUs that have satisfied both conditions will be settled in future instalments under their terms.
Roivant Sciences Ltd. director Melissa B. Epperly exercised options for 17,750 common shares on October 1, 2026, at $4.46 per share. She sold 16,850 shares at a weighted-average $36.08 per share (range $35.46–$36.45) and 900 shares at a weighted-average $36.57 per share (range $36.48–$36.72), under a Rule 10b5-1 trading plan adopted March 30, 2026. Her reported stock-option balance following the transaction was 151,416 options.
Roivant Sciences Ltd. CEO Matthew Gline reported the disposition of 76,171 Common Shares on September 30, 2026, as part of the issuer’s net settlement of previously granted RSUs to satisfy applicable tax withholding obligations upon vesting and settlement. The reported price was $36.57 per share, and his direct holdings following the transaction were 16,583,774 Common Shares.
Roivant Sciences Ltd. reported that President and Vant Chair Frank Torti acquired 40,309 common shares through the issuer’s net settlement of previously granted RSUs on September 30, 2026, to satisfy applicable tax withholding obligations. The reported price was $36.57 per share; Frank Torti held 13,495,893 common shares following the transaction. No Rule 10b5-1 plan is reported.
Roivant Sciences Ltd. President & CIO Mayukh Sukhatme had 46,879 common shares withheld through issuer net settlement on September 30, 2026, to satisfy tax withholding obligations tied to the vesting and settlement of previously granted RSUs. The reported price was $36.57 per share. He directly held 18,583,860 common shares following the transaction.
Roivant Sciences Ltd. officer Eric Venker, whose title is President & Immunovant CEO, exercised options for 200,000 common shares at a $3.85 per-share exercise price and sold 200,000 common shares on September 30, 2026. The shares were sold at a weighted average price of $36.62 per share in multiple transactions ranging from $36.49 to $36.76; the sales were made under a Rule 10b5-1 trading plan adopted on March 28, 2025. After the exercise, the reported direct stock-option position was 3,644,834 shares.
Roivant Sciences Ltd. (ROIV) reports that Chief Accounting Officer Jennifer Humes had 3,880 Common Shares withheld on September 20, 2026, at $39.77 per share to satisfy tax withholding obligations upon vesting and settlement of previously granted RSUs. After this tax-withholding disposition, she directly holds 106,419 Common Shares, which include shares acquired under the company’s Employee Stock Purchase Plan. No transactions are reported as made under a Rule 10b5-1 trading plan.
Roivant Sciences Ltd. (ROIV) reported that Chief Financial Officer Richard Pulik had 2,129 common shares withheld on September 20, 2026 to satisfy tax withholding obligations upon vesting of previously granted RSUs. The transaction was a net share settlement, not an open-market sale, and left him holding 269,681 common shares directly.
Roivant Sciences Ltd. (ROIV) reported that director Keith S. Manchester received equity compensation on September 16, 2026. He was granted 5,054 Common Shares in the form of restricted stock units and stock options for 10,531 Common Shares at an exercise price of $39.57 per share.
Both the RSUs and options are scheduled to vest 100% on September 16, 2027, subject to his continued service as a director. After the RSU grant, he directly holds 1,753,457 Common Shares. The options expire on September 15, 2036, and no Rule 10b5-1 trading plan is reported.
Roivant Sciences Ltd. (ROIV) reported that director Daniel Allen Gold received equity awards on September 16, 2026. He was granted 10,531 stock options to purchase Common Shares at an exercise price of $39.57 per share, expiring September 15, 2036, and an annual award of 5,054 RSUs, all vesting 100% on September 16, 2027, subject to continued board service. Following these grants, he directly holds 8,965,815 Common Shares. No Rule 10b5-1 trading plan is reported.
Roivant Sciences Ltd. (ROIV) reported that director Oren Ilan received equity awards on September 16, 2026 under the company's 2021 Equity Incentive Plan and Non-Employee Director Compensation Policy. He was granted 10,531 stock options to purchase Common Shares at an exercise price of $39.57 per share, expiring on September 15, 2036, and 5,054 restricted stock units (RSUs) covering Common Shares. Both the RSUs and the stock options are scheduled to vest 100% on September 16, 2027, subject to his continued service as a director. Following the RSU grant, he directly owned 123,680 Common Shares.
Roivant Sciences Ltd. (ROIV) reported that director James C. Momtazee received equity awards on September 16, 2026. He was granted 5,054 RSUs covering Common Shares and a stock option for 10,531 shares at an exercise price of $39.57 per share. Both awards are scheduled to vest 100% on September 16, 2027, subject to his continued service as a director. Following these awards, he directly holds 111,959 Common Shares and an option to purchase 10,531 shares. No Rule 10b5-1 trading plan is reported.
Roivant Sciences Ltd. (ROIV) reported that director Meghan Fitzgerald received equity-based compensation on September 16, 2026. She was granted 10,531 stock options to purchase Common Shares at an exercise price of $39.57 per share, expiring on September 15, 2036, and 5,054 restricted stock units (RSUs) for Common Shares.
Both the RSUs and the stock options were granted under Roivant’s 2021 Equity Incentive Plan and Non-Employee Director Compensation Policy and are scheduled to vest 100% on September 16, 2027, subject to her continued service as a director. After the RSU grant, she directly holds 41,162 Common Shares. No Rule 10b5-1 trading plan is reported.
Roivant Sciences Ltd. (ROIV) reported that director Melissa B. Epperly received annual equity awards on September 16, 2026. She was granted 10,531 stock options to purchase Common Shares at an exercise price of $39.57 per share and 5,054 restricted stock units, all as direct holdings. The RSUs and the options are scheduled to vest 100% on September 16, 2027, subject to her continued service as a director. Following these awards, she directly holds 14,954 Common Shares and 10,531 options.
Roivant Sciences Ltd. (ROIV) director Melissa B. Epperly reported open-market sales of Roivant Common Shares on September 15, 2026 under a pre-arranged Rule 10b5-1 trading plan adopted on March 30, 2026. She sold 4,338 shares at a weighted average price of $39.65 and 600 shares at a weighted average price of $40.38, with each sale executed in multiple trades within disclosed price ranges.
Roivant Sciences Ltd. (ROIV) director Meghan Fitzgerald reported open-market sales of Roivant common shares. On September 15, 2026, she sold 4,712 shares at a weighted average price of $39.68 per share and 400 shares at a weighted average price of $40.45 per share. The prices reflect multiple trades in ranges of $39.26–$40.25 and $40.28–$40.51, respectively, and all sales were effected under a Rule 10b5-1 trading plan adopted on March 30, 2026.
Roivant Sciences Ltd. (ROIV) reported that director Daniel Allen Gold had 5,133 Common Shares withheld on September 10, 2026 to satisfy tax withholding obligations in connection with the vesting and settlement of previously granted shares under the Non-Employee Director Compensation Plan. After this net-share tax withholding, he holds 8,960,761 Common Shares directly.
Roivant Sciences Ltd. (ROIV) director Oren Ilan reported a disposition of 2,378 Common Shares of the company on September 10, 2026. The shares were withheld by the issuer as a net settlement to cover applicable tax withholding obligations upon vesting of previously granted director equity awards. Following this tax-withholding transaction, Ilan directly holds 118,626 Common Shares of Roivant Sciences Ltd. No transactions were reported under a Rule 10b5-1 trading plan.
Roivant Sciences Ltd. (ROIV) reported that director Melissa B. Epperly had 2,179 Common Shares withheld on September 10, 2026, as a tax-withholding disposition connected to the vesting and settlement of previously granted shares under the Non-Employee Director Compensation Plan. After this net-share settlement for tax liabilities, she directly holds 14,838 Common Shares.
Roivant Sciences Ltd. (ROIV) director Meghan Fitzgerald had 1,743 Common Shares withheld on September 10, 2026 as a net settlement to satisfy tax withholding obligations tied to vesting of previously granted director equity awards. The shares were valued at $40.94 per share, leaving her with 41,220 Common Shares held directly after this transaction. No Rule 10b5-1 trading plan is reported for this disposition.
Roivant Sciences Ltd. (ROIV) director James C. Momtazee reported a Form 4 transaction involving the withholding of 2,905 Common Shares on September 10, 2026. The shares were withheld at $40.94 per share to satisfy tax withholding obligations upon vesting of equity granted under the company’s Non-Employee Director Compensation Plan, leaving him with 106,905 Common Shares held directly.
Roivant Sciences Ltd. (ROIV) director Meghan Fitzgerald reported an option exercise and same-day sale of common shares. On September 8, 2026, she exercised options for 20,000 shares at $8.80 per share, then sold 20,000 common shares at a weighted average price between $39.90 and $40.00 per share under a Rule 10b5-1 trading plan. Following the exercise, she held 18,578 stock options that remain exercisable until April 19, 2033.
Roivant Sciences Ltd. (ROIV) reported that officer Eric Venker, President & Immunovant CEO, exercised stock options for 200,000 Common Shares at an exercise price of $3.85 per share and on the same date sold an aggregate of 200,000 Common Shares in multiple transactions at weighted average prices of $35.63 and $36.44 per share, under a Rule 10b5-1 trading plan adopted on March 28, 2025. Following the option exercise, Venker reported 3,844,834 stock options remaining directly held.
Roivant Sciences Ltd. (ROIV) reported that its CFO, Richard Pulik, had 5,749 Common Shares withheld on 2026-08-20 to satisfy tax withholding obligations upon the vesting and settlement of previously granted RSUs. This "net settlement" left him with 271,810 Common Shares held directly, including shares purchased under the company’s Employee Stock Purchase Plan.
Roivant Sciences Ltd. (ROIV) reported an insider equity event involving Eric Venker, President & Immunovant CEO. On 2026-08-20, 13,909 common shares were withheld in a code F transaction at $36.84 per share as a net settlement of RSUs to cover tax withholding upon vesting. Following this withholding, Venker’s directly held stake is reported as 1,599,154 common shares. This reflects tax-related share settlement rather than an open-market sale.
Roivant Sciences Ltd. (ROIV) reported that President & CIO Mayukh Sukhatme exercised stock options and sold the resulting common shares over three days. He exercised options covering 335,174 Common Shares at an exercise price of $3.85 per share, fully vested per the award footnote, and received an equal number of Common Shares. On August 19, 20 and 21, 2026, he sold 172,899, 17,519 and 144,756 Common Shares, respectively, at weighted average prices of $37.17, $37.30 and $36.48 per share in multiple transactions within the stated price ranges.
Roivant Sciences Ltd. (ROIV) reported that President & CIO Mayukh Sukhatme exercised stock options and sold common shares over three days. On August 14, 17, and 18, 2026, options with a $3.85 exercise price were exercised to acquire an aggregate of 664,826 common shares, which were then sold in multiple open-market transactions at weighted average prices reported as approximately $36.23, $36.25, $36.59, and $37.18 per share, with actual trade prices ranging from $36.10 to $37.30, as described in the footnotes.
Roivant Sciences Ltd. president and Immunovant CEO Eric Venker reported an option exercise and related share sale. On 2026-07-27 he exercised stock options for 200,000 Common Shares at $3.85 per share from a fully vested award, leaving 4,044,834 options of this grant outstanding, expiring April 19, 2032. He then sold 200,000 Common Shares at a weighted average price of $34.95 (with trades between $34.62 and $35.56), with the filing indicating use of a Rule 10b5-1 trading plan.
MOMTAZEE JAMES C reported acquisition or exercise transactions in this Form 4 filing.
Roivant Sciences Ltd. director James C. Momtazee received an award of 405 Common Shares on July 17, 2026 under the Non-Employee Director Compensation Plan at $0.00 per share. The award was fully vested on grant, bringing his directly held stake to 109,810 Common Shares.
Epperly Melissa B, reported acquisition or exercise transactions in this Form 4 filing.
Roivant Sciences Ltd. director Melissa B. Epperly received a grant of 543 Common Shares on July 17, 2026 under the company’s Non-Employee Director Compensation Plan. The award was fully vested at grant and increased her directly held stake to 17,017 Common Shares.
Roivant Sciences Ltd. director Oren Ilan received an award of 775 Common Shares on July 17, 2026 at $0.0000 per share under the company’s Non-Employee Director Compensation Plan, fully vested as of the grant date.
After this grant, Ilan directly holds 121,004 Common Shares; the transaction is reported as a grant/award acquisition and was not made under a Rule 10b5-1 trading plan.
Roivant Sciences Ltd. director and CEO Matthew Gline reported a routine tax-related share disposition tied to restricted stock units. On the vesting and settlement of previously granted RSUs, the company withheld 76,171 common shares, valued at $35.39 per share, to cover applicable tax obligations through a net settlement. Following this transaction, Gline directly holds 16,659,945 common shares, indicating he retains a substantial equity position in the company and that the reported disposition reflects tax withholding rather than an open-market sale.
Roivant Sciences Ltd. director Meghan Fitzgerald reported an option exercise paired with an open-market sale of common shares. She exercised stock options to acquire 10,000 common shares at $8.80 per share and on the same date sold 10,000 common shares at an average price of $34.90 per share.
Following these transactions, Fitzgerald directly holds 42,963 common shares of Roivant Sciences. The derivative entry shows 38,578 stock options remaining after the exercise, indicating she continues to have a meaningful option position as well as a direct equity stake.
Roivant Sciences Ltd. reported that President and Vant Chair Frank Torti had 40,310 common shares withheld on June 30, 2026 to cover tax obligations. The shares were "net settled" from previously granted RSUs when they vested, rather than sold in the open market.
After this tax-withholding disposition, Torti directly holds 13,536,202 common shares, indicating this was a routine compensation-related event rather than a change in his overall investment stance.
Roivant Sciences Ltd. director and President & CIO Mayukh Sukhatme had 46,878 Common Shares withheld on June 30, 2026 at $35.39 per share. This was a tax-withholding disposition tied to the vesting of previously granted RSUs, not an open-market trade. After this net settlement, he directly holds 18,630,739 Common Shares.
Roivant Sciences Ltd. director Melissa B. Epperly exercised stock options and sold shares of the company on June 29, 2026. She exercised options to acquire 17,750 Common Shares at an exercise price of $4.46 per share, increasing her direct common share holdings before subsequent sales.
That same day, she executed open-market sales totaling 17,750 Common Shares in two transactions: 2,748 shares at a weighted average price of $34.71 and 15,002 shares at a weighted average price of $34.32. The footnotes state these were filled across multiple trades within price ranges from $33.65 to $34.80. After the transactions, Epperly directly held 16,474 Common Shares and 169,166 stock options to purchase additional shares, with the option grant exercised here fully vested and expiring on July 19, 2032.
Roivant Sciences director Keith S. Manchester reported open-market sales totaling 1,638,163 Common Shares of Roivant Sciences Ltd. from June 26–30, 2026, at prices between $33.92 and $35.45 per share. The filing shows 200,000 shares sold from his direct holdings, leaving 1,748,403 shares held directly, and additional sales by QVT Financial Investment Cayman Ltd., which held 13,689,166 shares afterward. Manchester is a shareholder of QVT Financial Investment Cayman Ltd. but has no voting or investment control over it and disclaims beneficial ownership of those shares except for his pecuniary interest.
Roivant Sciences Ltd. reported insider-related share sales linked to an investment entity associated with director Daniel Allen Gold. QVT Financial Investment Cayman Ltd. completed open-market sales of a total of 1,438,163 common shares of Roivant Sciences over three days, at prices between $33.92 and $35.28 per share. After the most recent transaction, QVT Financial Investment Cayman Ltd. held 13,689,166 common shares indirectly. Gold is one of three directors of QVT Financial Investment Cayman Ltd., shares voting and investment control over these shares, and disclaims beneficial ownership except to the extent of his pecuniary interest.
Roivant Sciences Ltd. disclosed that investment firm QVT Financial LP, through QVT Financial Investment Cayman Ltd., executed open-market sales of a total of 1,438,163 common shares over three days at prices around $33.92–$35.28 per share. Following these transactions, QVT Financial Investment Cayman Ltd. held 13,689,166 common shares, while footnotes state that QVT Financial LP may be deemed to beneficially own 23,723,074 Roivant common shares across related entities, although it disclaims beneficial ownership beyond any pecuniary interest.
Roivant Sciences Ltd. President & CIO Mayukh Sukhatme reported an exercise-and-sell pattern over two days. On June 25 and 26, he exercised options to acquire a total of 1,000,000 Common Shares at $3.85 per share and sold 1,000,000 Common Shares in open-market transactions.
The sales were executed at weighted average prices of $34.13 and $34.08 per share, each representing multiple trades within disclosed price ranges. Following these transactions, Sukhatme directly held 18,677,617 Common Shares. The underlying options exercised were fully vested and are no longer outstanding.
Roivant Sciences Ltd. reported insider transactions by President & Immunovant CEO Eric Venker involving both an option exercise and open-market sales of common shares.
Venker exercised stock options for 200,000 Common Shares at a conversion price of $3.85 per share and received fully vested shares. On the same date, he sold 46,234 Common Shares at a weighted average price of $33.51 and 153,766 Common Shares at a weighted average price of $33.05 in multiple open-market transactions within disclosed price ranges. Following these moves, he directly held 1,613,063 Common Shares and 4,244,834 stock options to purchase additional shares.
Roivant Sciences Ltd. CFO Richard Pulik reported a routine share disposition tied to equity compensation. On the RSU vesting date, 2,129 common shares at $31.43 per share were withheld by the company to satisfy tax withholding obligations through a net settlement of previously granted RSUs. Following this tax-related transfer, Pulik directly holds 276,420 common shares of Roivant Sciences Ltd.
Roivant Sciences Ltd. Chief Accounting Officer Jennifer Humes reported a routine tax-related share disposition. On this Form 4, 3,582 common shares were surrendered at a value of $31.43 per share to cover tax withholding tied to the vesting of previously granted RSUs. After this net settlement, she directly holds 109,782 common shares, indicating the transaction reflects compensation and tax obligations rather than an open-market sale.
Roivant Sciences Ltd. President & Immunovant CEO Eric Venker reported a set of transactions involving company shares. He exercised stock options to acquire 200,000 Common Shares at $3.85 per share, then sold 200,000 Common Shares in an open-market transaction at a weighted average price of $30.27 per share. Separately, 34,483 Common Shares were surrendered through a net settlement to cover tax withholding obligations on vested RSUs, which is not an open-market sale. After these transactions, Venker directly holds 1,613,063 Common Shares.
Roivant Sciences Ltd. CFO Richard Pulik reported a tax-withholding share disposition related to restricted stock units (RSUs). On this event, 18,962 common shares were withheld at a value of $32.41 per share to cover tax obligations triggered by the vesting and settlement of previously granted RSUs. After this non‑market transaction, Pulik directly holds 278,549 common shares, indicating he retains a substantial equity position in the company.